Path to Prevention Platform Trial in Early-Stage Neuronal Alpha-Synuclein Disease: Study Design
The development of biologically targeted therapeutics (BTTs) that slow Parkinson's disease progression has been hampered by a reliance on testing interventions in clinically defined populations with…